Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Beam Therapeutics Analyst Ratings
Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Travere Therapeutics (TVTX) and Oscar Health (OSCR)
Wedbush: Reiterates the Beam Therapeutics (BEAM.US) rating and adjusted from better than market to better than market rating, with a target price of $57.00.
Beam Therapeutics Analyst Ratings
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
Beam Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating
Barclays: Maintaining a wait-and-see rating for Beam Therapeutics (BEAM.US) shares, and the target price was adjusted from $26.00 to $42.00.
Beam Therapeutics Analyst Ratings
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating
JP Morgan Upgrades Beam to Overweight, Cites AATD Therapy Potential
JP Morgan Upgrades Beam Therapeutics to Overweight, Raises Price Target to $40